Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist for the symptomatic treatment of benign prostatic hyperplasia.
Meyer
M D
MD
Neurological and Urological Diseases Research, Abbott Laboratories, Abbott Park, Illinois 60064-3500, USA.
Altenbach
R J
RJ
Basha
F Z
FZ
Carroll
W A
WA
Drizin
I
I
Elmore
S W
SW
Ehrlich
P P
PP
Lebold
S A
SA
Tietje
K
K
Sippy
K B
KB
Wendt
M D
MD
Plata
D J
DJ
Plagge
F
F
Buckner
S A
SA
Brune
M E
ME
Hancock
A A
AA
Kerwin
J F
JF
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000138:chemical synthesis* / Q000627:therapeutic use; D000818:Animals; D004285:Dogs; D006801:Humans; D007211:Indoles / Q000138:chemical synthesis* / Q000627:therapeutic use; D054833:Isoindoles; D008297:Male; D008956:Models, Chemical; D011224:Prazosin / Q000031:analogs & derivatives / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011744:Pyrimidinones / Q000138:chemical synthesis* / Q000627:therapeutic use; D051381:Rats; D018340:Receptors, Adrenergic, alpha-1; D013449:Sulfonamides / Q000627:therapeutic use; D000077409:Tamsulosin
C108685:A 131701; C547713:ADRA1A protein, human; D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D007211:Indoles; D054833:Isoindoles; D011744:Pyrimidinones; D018340:Receptors, Adrenergic, alpha-1; D013449:Sulfonamides; C041226:Terazosin; D000077409:Tamsulosin; D011224:Prazosin